RÉSUMÉ
BACKGROUND: Encephalitis continues to result in substantial morbidity and mortality worldwide. Advances in diagnosis and management have been limited, in part, by a lack of consensus on case definitions, standardized diagnostic approaches, and priorities for research. METHODS: In March 2012, the International Encephalitis Consortium, a committee begun in 2010 with members worldwide, held a meeting in Atlanta to discuss recent advances in encephalitis and to set priorities for future study. RESULTS: We present a consensus document that proposes a standardized case definition and diagnostic guidelines for evaluation of adults and children with suspected encephalitis. In addition, areas of research priority, including host genetics and selected emerging infections, are discussed. CONCLUSIONS: We anticipate that this document, representing a synthesis of our discussions and supported by literature, will serve as a practical aid to clinicians evaluating patients with suspected encephalitis and will identify key areas and approaches to advance our knowledge of encephalitis.
Sujet(s)
Algorithmes , Techniques et procédures diagnostiques/normes , Encéphalite/diagnostic , Adulte , Enfant , Consensus , HumainsRÉSUMÉ
The laboratory diagnostic strategy used to determine the etiology of encephalitis in 203 patients is reported. An etiological diagnosis was made by first-line laboratory testing for 111 (55%) patients. Subsequent testing, based on individual case reviews, resulted in 17 (8%) further diagnoses, of which 12 (71%) were immune-mediated and 5 (29%) were due to infection. Seventy-five cases were of unknown etiology. Sixteen (8%) of 203 samples were found to be associated with either N-methyl-d-aspartate receptor or voltage-gated potassium channel complex antibodies. The most common viral causes identified were herpes simplex virus (HSV) (19%) and varicella-zoster virus (5%), while the most important bacterial cause was Mycobacterium tuberculosis (5%). The diagnostic value of testing cerebrospinal fluid (CSF) for antibody was assessed using 139 samples from 99 patients, and antibody was detected in 46 samples from 37 patients. Samples collected at 14 to 28 days were more likely to be positive than samples taken 0 to 6 days postadmission. Three PCR-negative HSV cases were diagnosed by the presence of virus-specific antibody in the central nervous system (CNS). It was not possible to make an etiological diagnosis for one-third of the cases; these were therefore considered to be due to unknown causes. Delayed sampling did not contribute to these cases. Twenty percent of the patients with infections with an unknown etiology showed evidence of localized immune activation within the CNS, but no novel viral DNA or RNA sequences were found. We conclude that a good standard of clinical investigation and thorough first-line laboratory testing allows the diagnosis of most cases of infectious encephalitis; testing for CSF antibodies allows further cases to be diagnosed. It is important that testing for immune-mediated causes also be included in a diagnostic algorithm.
Sujet(s)
Algorithmes , Techniques de laboratoire clinique/méthodes , Encéphalite/diagnostic , Encéphalite/étiologie , Adolescent , Adulte , Anticorps/liquide cérébrospinal , Infections bactériennes/diagnostic , Infections bactériennes/microbiologie , Liquide cérébrospinal/immunologie , Enfant , Enfant d'âge préscolaire , Études de cohortes , Diagnostic différentiel , Angleterre , Femelle , Humains , Maladies du système immunitaire/diagnostic , Mâle , Adulte d'âge moyen , Études prospectives , Maladies virales/diagnostic , Maladies virales/virologie , Jeune adulteRÉSUMÉ
Defining the causal relationship between a microbe and encephalitis is complex. Over 100 different infectious agents may cause encephalitis, often as one of the rarer manifestations of infection. The gold-standard techniques to detect causative infectious agents in encephalitis in life depend on the study of brain biopsy material; however, in most cases this is not possible. We present the UK perspective on aetiological case definitions for acute encephalitis and extend them to include immune-mediated causes. Expert opinion was primarily used and was supplemented by literature-based methods. Wide usage of these definitions will facilitate comparison between studies and result in a better understanding of the causes of this devastating condition. They provide a framework for regular review and updating as the knowledge base increases both clinically and through improvements in diagnostic methods. The importance of new and emerging pathogens as causes of encephalitis can be assessed against the principles laid out here.
Sujet(s)
Encéphalite/étiologie , Maladie aigüe , Amibiase/complications , Amibiase/diagnostic , Infections bactériennes/complications , Infections bactériennes/diagnostic , Encéphalite/diagnostic , Encéphalite/microbiologie , Humains , Rickettsioses/complications , Rickettsioses/diagnostic , Toxoplasmose/complications , Toxoplasmose/diagnostic , Royaume-Uni/épidémiologie , Maladies virales/complications , Maladies virales/diagnosticRÉSUMÉ
BACKGROUND: A retrospective study of the clinical, epidemiologic, and virologic features of norovirus gastroenteritis in 12 adult allogeneic hematopoietic stem cell transplant (HSCT) recipients. METHODS: Norovirus infection was diagnosed by reverse-transcriptase polymerase chain reaction. Strains were genotyped by nucleic acid sequence of the most highly conserved region of the norovirus gene encoding the capsid S (shell) domain. RESULTS: Ten of 12 patients presented with vomiting of short duration, but diarrhea was present in all. The median time from onset to norovirus diagnosis was 1 month (range, 0.25-6.0 months). Eleven patients were receiving immunosuppression when norovirus infection was diagnosed: 8 for graft-versus-host disease (GVHD) in an organ other than gut, 1 for previous gut GVHD, and 2 for presumed gut GVHD that proved to be norovirus gastroenteritis. Six patients required enteral or parenteral nutrition for severe weight loss. In 10 patients, diarrhea lasted a median of 3 months (range, 0.5-14 months) and virus was shed at a high level throughout. The remaining 2 patients died after 4 months of diarrhea (one died of unrelated complications, and the other died of malnutrition). The noroviruses found were GII (untyped), GII-3, GII-4, and GII-7 in 1, 1, 9, and 1 patients, respectively. Eleven of the 12 patients had acquired their infection in the community. Phylogenetic analysis of the GII-4 strains demonstrated that all differed. CONCLUSIONS: Noroviruses are a hitherto unsuspected cause of prolonged morbidity and mortality in adults after allogeneic HSCT. The use of reverse-transcriptase polymerase chain reaction to detect high viral load levels in feces distinguishes norovirus gastroenteritis from gut GVHD.
Sujet(s)
Infections à Caliciviridae/épidémiologie , Gastroentérite/épidémiologie , Transplantation de cellules souches hématopoïétiques/effets indésirables , Norovirus/isolement et purification , Transplantation homologue/effets indésirables , Adolescent , Adulte , Infections à Caliciviridae/virologie , Fèces/virologie , Femelle , Gastroentérite/virologie , Humains , Mâle , Adulte d'âge moyen , Données de séquences moléculaires , Norovirus/classification , Norovirus/génétique , ARN viral/génétique , Études rétrospectives , RT-PCR/méthodes , Analyse de séquence d'ADN , Jeune adulteRÉSUMÉ
These guidelines on the management of HSV, VZV and EBV infection in patients with hematological malignancies and after SCT were prepared by the European Conference on Infections in Leukemia following a predefined methodology. A PubMed search was conducted using the appropriate key words to identify studies pertinent to management of HSV, VZV and EBV infections. References of relevant articles and abstracts from recent hematology and SCT scientific meetings were also reviewed. Prospective and retrospective studies identified from the data sources were evaluated, and all data deemed relevant were included in this analysis. The clinical and scientific background was described and discussed, and the quality of evidence and level of recommendation were graded according to the Centers for Disease Control criteria.
Sujet(s)
Tumeurs hématologiques/complications , Transplantation de cellules souches hématopoïétiques/effets indésirables , Infections à Herpesviridae/diagnostic , Infections à Herpesviridae/traitement médicamenteux , Prise en charge de la maladie , Infections à virus Epstein-Barr/diagnostic , Infections à virus Epstein-Barr/traitement médicamenteux , Tumeurs hématologiques/thérapie , Herpès/diagnostic , Herpès/traitement médicamenteux , Zona/diagnostic , Zona/traitement médicamenteux , Infections à Herpesviridae/étiologie , HumainsRÉSUMÉ
A patient with severe chickenpox was admitted to a negative-pressure isolation room. He remained sedated, intubated and mechanically ventilated throughout his admission. He was managed only by nurses immune to chickenpox. A non-immune male nurse occasionally handed equipment through the doorway, without entering the room. Ten days later, he also developed chickenpox. Sequencing of viruses from the patient and nurse showed the same rare genotype, indicating nosocomial transmission. An experimental model demonstrated that, despite negative pressure, opening the door could have resulted in transport of infectious air out of the isolation room, leading to a breakdown in isolation conditions.
Sujet(s)
Pression de l'air , Varicelle/transmission , Isolateurs pour patients , Varicelle/virologie , Environnement contrôlé , Génotype , Herpèsvirus humain de type 3/génétique , Herpèsvirus humain de type 3/isolement et purification , Humains , Transmission de maladie infectieuse du patient au professionnel de santé , Mâle , Adulte d'âge moyen , Analyse de séquence d'ADN , Similitude de séquencesRÉSUMÉ
BACKGROUND: Primary human herpesvirus-6 and -7 (HHV-6/-7) infections cause febrile illness sometimes complicated by convulsions and rarely encephalopathy. AIMS: To explore the extent of such HHV-6 and -7 induced disease in young children. METHODS: In a three year prospective study in Britain and Ireland, 205 children (2-35 months old) hospitalised with suspected encephalitis and/or severe illness with fever and convulsions were reported via the British Paediatric Surveillance Unit network. Blood samples were tested for primary HHV-6 and -7 infections. RESULTS: 26/156 (17%) of children aged 2-23 months had primary infection (11 HHV-6; 13 HHV-7; two with both viruses) coinciding with the acute illness; this was much higher than the about three cases expected by chance. All 26 were pyrexial; 25 had convulsions (18 status epilepticus), 11 requiring ventilation. Median hospital stay was 7.5 days. For HHV-6 primary infection the median age was 53 weeks (range 42-94) and the distribution differed from that of uninfected children; for HHV-7, the median was 60 weeks (range 17-102) and the distribution did not differ for the uninfected. Fewer (5/15) children with primary HHV-7 infection had previously been infected with HHV-6 than expected. CONCLUSIONS: Primary HHV-6 and HHV-7 infections accounted for a significant proportion of cases in those <2 years old of severe illness with fever and convulsions requiring hospital admission; each virus contributed equally. Predisposing factors are age for HHV-6 and no previous infection with HHV-6 for HHV-7. Children with such neurological disease should be investigated for primary HHV-6/-7 infections, especially in rare cases coinciding by chance with immunisation to exclude misdiagnosis as vaccine reactions.
Sujet(s)
Encéphalite virale/épidémiologie , Herpèsvirus humain de type 6 , Herpèsvirus humain de type 7 , Infections à roséolovirus/épidémiologie , Enfant d'âge préscolaire , Encéphalite virale/virologie , Exanthème subit/épidémiologie , Fièvre/épidémiologie , Fièvre/virologie , Enquêtes de santé , Humains , Nourrisson , Irlande/épidémiologie , Prévalence , Études prospectives , Crises épileptiques/épidémiologie , Crises épileptiques/virologie , Royaume-Uni/épidémiologieRÉSUMÉ
Patients undergoing haemopoietic stem cell transplants (HSCT) are at high risk of varicella zoster virus (VZV) reactivation, with a significant incidence of dissemination. This study reports a retrospective analysis of 247 allogeneic HSCT recipients receiving anti-viral prophylaxis with low-dose oral aciclovir 400 mg/day, administered until immunosuppression was discontinued and the CD4(+) cell count exceeded 200/mm(3). Viral reactivation was successfully suppressed by aciclovir prophylaxis, with only one case of breakthrough infection. The cumulative incidence of zoster infection at 1 year post transplant was 2% and at 5 years 34%. In all, 64 patients discontinued prophylaxis. Zoster developed in 26 of these, giving a cumulative incidence of infection at 1 year after stopping aciclovir of 39% and at 3 years 44%. Infection occurred in a localised dermatomal distribution in 93% of cases. This supports previous findings that aciclovir prophylaxis prevents early VZV reactivation, although the long-term incidence is not affected as infection occurs once prophylaxis is discontinued. Such infection, however, is mild and localised. This study does not support the idea that use of such low-dose aciclovir regimens reduces the zoster incidence by permitting subclinical reactivation during prophylaxis, and therefore the re-establishment of protective anti-viral immunity.
Sujet(s)
Aciclovir/usage thérapeutique , Antiviraux/usage thérapeutique , Varicelle/prévention et contrôle , Transplantation de cellules souches hématopoïétiques/effets indésirables , Zona/prévention et contrôle , Herpèsvirus humain de type 3/métabolisme , Transplantation homologue/effets indésirables , Adulte , Lymphocytes T CD4+/cytologie , Varicelle/étiologie , Études de cohortes , Zona/étiologie , Humains , Immunosuppresseurs/pharmacologie , Leucémies/thérapie , Adulte d'âge moyen , Complications postopératoires , Études rétrospectives , Facteurs de risque , Lymphocytes T/métabolisme , Facteurs temps , Conditionnement pour greffe/méthodesRÉSUMÉ
BACKGROUND: Human herpesviruses-6 and -7 (HHV-6/7) are widespread in all populations. In some individuals HHV-6 is found integrated into human chromosomes, which results in a high viral load in blood. HHV-6 variant B (HHV-6B) and HHV-7 primary infections, although usually silent, not infrequently cause the childhood exanthem roseola infantum and are sometimes accompanied by neurological illness. HHV-6 variant A (HHV-6A) is not associated with any disease. OBJECTIVES: The present review focuses on the immunocompetent individual and considers the epidemiology of the two viruses and their role as human pathogens. It discusses the importance of satisfactory diagnostic tests to distinguish them, compares those currently available, and recommends how best to differentiate primary from persistent infection in each case. RESULTS: It is explained that at the present time antibody avidity immunofluorescence tests are the most reliable discriminators of the two types of infection. In primary infection these tests can be supplemented by PCR for viral DNA in blood but careful interpretation is required for HHV-6 in view of the high persistent viral DNA load seen with chromosomal integration. Since the contribution of primary HHV-6 and -7 infections to the burden of severe neurological illness in young children is only now emerging as significant, the need to test for these viruses in such cases is stressed. CONCLUSIONS: 1. Primary HHV-6/7 infections must be distinguished from persistent infections. 2. Chromosomal integration of HHV-6 requires urgent study. 3. HHV-6A/B must be distinguished in clinical situations. 4. Where serious neurological disease/encephalitis is temporally related to immunisation it is particularly important to test for HHV-6/7 primary infection since otherwise the condition might wrongly be diagnosed as a vaccine reaction. 5. Because less is currently known about HHV-7 and HHV-6A than HHV-6B, future studies should concentrate on the former two. 6. Improvements in diagnostic tests are required for each virus.
Sujet(s)
Herpèsvirus humain de type 6 , Herpèsvirus humain de type 7 , Infections à roséolovirus/diagnostic , Infections à roséolovirus/immunologie , Exanthème subit/diagnostic , Exanthème subit/virologie , Humains , Immunocompétence , Incidence , Infections à roséolovirus/épidémiologie , Infections à roséolovirus/virologieRÉSUMÉ
BACKGROUND: The combination of both PCR and intrathecal antibody studies is recommended to confirm or refute the diagnosis of herpes simplex encephalitis (HSE). AIM: To investigate the pattern of use of laboratory tests in the diagnosis of suspected cases of HSE, and to determine the final diagnosis in cases proven not to be HSE. DESIGN: Structured audit. METHODS: We reviewed the case-notes of all patients who, over a five-year time period, presented with suspected encephalitis; and/or were prescribed aciclovir. Clinical and laboratory criteria were used to categorize the likelihood of HSE. RESULTS: We identified 222 patients: 10 (5%) had definite HSE, 24 (10%) possible HSE, and 144 (65%) a definite alternative diagnosis. In 44 (20%), no final diagnosis was made, but the diagnosis of HSE was excluded. PCR was performed in 68 (31%), intrathecal antibody studies in 24 (11%), and brain biopsy in 17 (8%). A wide range of diseases mimicked HSE, but most common were inflammatory diseases and other infections of the central nervous system. DISCUSSION: Laboratory tests, particularly intrathecal antibody assays, are under-used in the diagnosis of HSE. Although early empirical treatment of suspected HSE is essential, confirmation or exclusion of the diagnosis is equally important to avoid overlooking alternative diagnoses. Identification of the aetiology of encephalitis is of particular importance, given the current concerns of emerging infections and bioterrorism.
Sujet(s)
Encéphalite à herpès simplex/diagnostic , Audit médical/méthodes , Aciclovir/usage thérapeutique , Anticorps antiviraux/analyse , Antiviraux/usage thérapeutique , Encéphale/immunologie , Diagnostic différentiel , Encéphalite à herpès simplex/liquide cérébrospinal , Encéphalite à herpès simplex/traitement médicamenteux , Gènes viraux , Humains , Réaction de polymérisation en chaîne/méthodes , Valeur prédictive des tests , Études rétrospectives , Simplexvirus/génétiqueRÉSUMÉ
We investigated primary human herpesvirus-6 and -7 (HHV-6, HHV-7) infections as a cause of rashes incorrectly diagnosed as measles in Brazilian children. Sera from 124 patients, aged 4 months to 17 years, from the states of Rio de Janeiro and Espirito Santo, in whom measles, rubella and parvovirus B19 infections had been excluded, were studied using indirect immunofluorescence antibody avidity tests; 38 (31%) had evidence of primary HHV-6 and/or HHV-7 infections. Twenty four children had primary HHV-6 infection, either recent or coincident with the rash, and similarly 31 had primary HHV-7 infection. Remarkably, almost half (17) of primary infections were dual HHV-6 and HHV-7 infections with the majority, 12 (71%), in children less than 1 year old. HHV-7 infection occurred earlier than previously reported, perhaps due to socioeconomic and tropical conditions in this region of Brazil, and thus coincided with the HHV-6 infections. This study also highlights the difficulties of diagnosing a rash illness on clinical grounds alone.
Sujet(s)
Infections à Herpesviridae/diagnostic , Rougeole/diagnostic , Adolescent , Anticorps antiviraux/analyse , Brésil/épidémiologie , Enfant , Enfant d'âge préscolaire , Diagnostic différentiel , Erreurs de diagnostic , Femelle , Technique d'immunofluorescence indirecte , Infections à Herpesviridae/épidémiologie , Herpèsvirus humain de type 6 , Herpèsvirus humain de type 7 , Humains , Nourrisson , Mâle , Rougeole/épidémiologieRÉSUMÉ
A 27 year old woman developed a vesicular genital rash and cerebellar dysfunction with progressive neurological deterioration suggesting brain stem encephalitis. Respiratory support was required. Magnetic resonance imaging (MRI) of the brain on day 7 showed signal hyperintensity in the central medulla and ventral pons, typical of acute inflammation. The course was severe and relapse occurred. MRI on day 33 showed a haemorrhagic area in the medulla. Treatment with aciclovir/valaciclovir eventually led to gradual recovery. Herpes simplex virus 2 (HSV-2) DNA was detected in CSF on days 11 and 14. HSV-2 was also detected in vesicle fluid from the genital rash. Serum was initially negative for HSV-1 and HSV-2 antibodies, but convalescent samples showed seroconversion to HSV-2, indicating primary infection. Intrathecal synthesis of oligoclonal IgG bands specific for HSV was identified in the CSF. It is important to differentiate HSV-2 from HSV-1, and primary from initial or reactivated infection, so that prolonged aciclovir treatment followed by prophylaxis is instituted to prevent the high likelihood of symptomatic relapse in primary HSV-2 infection.
Sujet(s)
Tronc cérébral/anatomopathologie , Encéphalite à herpès simplex/anatomopathologie , Herpèsvirus humain de type 2/pathogénicité , Aciclovir/usage thérapeutique , Adulte , Antiviraux/usage thérapeutique , Tronc cérébral/virologie , ADN viral/analyse , Encéphalite à herpès simplex/traitement médicamenteux , Femelle , Humains , Immunoglobuline G/analyse , Imagerie par résonance magnétiqueRÉSUMÉ
The beta-herpesviruses, human herpesviruses-6 and -7 (HHV-6 and HHV-7), are closely related and have very similar biological behaviour. While HHV-6 is associated with encephalitis in immunosuppressed adults, HHV-7 is not recognised as a cause of neurological disease in such patients. This report describes the identification of a reactivated HHV-7 infection in the cerebrospinal fluid of an adult who presented with an acute myelitis 11 months after unrelated donor bone marrow transplant.
Sujet(s)
Transplantation de moelle osseuse/effets indésirables , Herpèsvirus humain de type 7/isolement et purification , Myélite/étiologie , Paraparésie spastique/étiologie , Infections à roséolovirus/étiologie , Anti-inflammatoires/usage thérapeutique , Liquide cérébrospinal/virologie , Maladie du greffon contre l'hôte/traitement médicamenteux , Maladie du greffon contre l'hôte/étiologie , Herpèsvirus humain de type 7/croissance et développement , Humains , Sujet immunodéprimé , Immunosuppresseurs/effets indésirables , Transfusion de lymphocytes , Mâle , Méthylprednisolone/usage thérapeutique , Adulte d'âge moyen , Myélome multiple/complications , Myélome multiple/thérapie , Myélite/traitement médicamenteux , Myélite/virologie , Paraparésie spastique/traitement médicamenteux , Paraparésie spastique/virologie , Transplantation homologue/effets indésirables , Vessie neurologique/étiologie , Activation viraleRÉSUMÉ
Sera from 118 children aged up to 4 years were tested by indirect immunofluorescence for human herpesvirus-6 and -7 (HHV-6 and HHV-7) antibodies. Antibody results were confirmed as true positives if the relevant viral DNA was detected in saliva or, in some cases of primary infection, by the finding of the relevant DNA in cerebrospinal fluid or serum. Results from samples taken from the 15 children less than 6 months old showed that HHV-6 and/or HHV-7 antibody was either absent or present at low titre suggesting persistent maternal antibody rather than true infection. The sensitivity, specificity, positive and negative predictive values of the HHV-6 IgG test were therefore based on the data from the 103 children older than 6 months and the results were 95, 84, 91 and 90%, respectively. Likewise, the sensitivity, specificity, positive and negative predictive values of the HHV-7 IgG test were 95, 76, 84 and 93%, respectively. There was limited cross-reactivity between HHV-6 and HHV-7 antibodies; where both HHV-6 and HHV-7 antibodies are detected, titres above 32 may be accepted as true positives but lower titres require confirmation by detection of the relevant viral DNA or, in the case of primary infection, by a rising antibody titre.
Sujet(s)
Anticorps antiviraux/sang , Herpèsvirus humain de type 6/immunologie , Herpèsvirus humain de type 7/immunologie , Immunoglobuline G/sang , Infections à roséolovirus/diagnostic , Enfant d'âge préscolaire , ADN viral/analyse , Technique d'immunofluorescence indirecte , Herpèsvirus humain de type 6/isolement et purification , Herpèsvirus humain de type 7/isolement et purification , Humains , Nourrisson , Valeur prédictive des tests , Infections à roséolovirus/virologie , Salive/virologie , Sensibilité et spécificitéRÉSUMÉ
Antibody avidity tests have been used to detect primary human herpesvirus-7 (HHV-7) infection in an immunocompetent 19-year-old man with encephalitis and flaccid paralysis for which all other suspected causes had been excluded. The finding of the viral DNA in the cerebrospinal fluid (CSF) but not in serum samples suggests that primary HHV-7 infection with invasion of the central nervous system and consequential disease had occurred. As almost all adults are infected with HHV-7 in early childhood, the present case of delayed primary infection with serious symptoms must be exceptionally rare and no cases of such late acquisition of the virus have been documented in the literature. This report of HHV-7 DNA in the CSF of an immunocompetent adult is also unique.
Sujet(s)
Encéphalite virale/complications , Encéphalite virale/virologie , Infections à Herpesviridae/complications , Infections à Herpesviridae/virologie , Herpèsvirus humain de type 7/physiologie , Paralysie/complications , Paralysie/virologie , Adulte , Affinité des anticorps , ADN viral/sang , ADN viral/liquide cérébrospinal , Infections à Herpesviridae/diagnostic , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/immunologie , Herpèsvirus humain de type 7/génétique , Herpèsvirus humain de type 7/immunologie , Humains , Immunoglobuline G/immunologie , Mâle , Réaction de polymérisation en chaîneRÉSUMÉ
Community-acquired respiratory virus infections are a cause of mortality after stem cell transplantation (SCT). A prospective study was performed at 37 centers to determine their frequency and importance. Additional cases were also collected to allow the analysis of risk factors for severe infection. Forty episodes were collected in the prospective study and 53 additional episodes through subsequent case collection. The frequency of documented respiratory virus infections was 3.5% among 819 allogeneic and 0.4% among 1154 autologous SCT patients transplanted during the study period. The frequency of lower respiratory tract infections (LRTI) was 2.1% among allogeneic and 0.2% among autologous SCT patients. The mortality within 28 days from diagnosis of a respiratory viral infection was 1.1% among allogeneic SCT while no autologous SCT patient died. The deaths of five patients (0.6%) were directly attributed to a respiratory virus infection (three RSV; two influenza A). On multivariate analysis, lymphocytopenia increased the risk for LRTI (P = 0.008). Lymphocytopenia was also a significant risk factor for LRTI in patients with RSV infections. The overall mortality in RSV infection was 30.4% and the direct RSV-associated mortality was 17.4%. For influenza A virus infection, the corresponding percentages were 23.0% and 15.3%. This prospective study supports the fact that community-acquired respiratory virus infections cause transplant-related mortality after SCT.
Sujet(s)
Transplantation de cellules souches hématopoïétiques/effets indésirables , Infections de l'appareil respiratoire/épidémiologie , Adolescent , Adulte , Sujet âgé , Enfant , Enfant d'âge préscolaire , Transplantation de cellules souches hématopoïétiques/mortalité , Humains , Nourrisson , Grippe humaine/épidémiologie , Grippe humaine/mortalité , Grippe humaine/thérapie , Adulte d'âge moyen , Études prospectives , Infections à virus respiratoire syncytial/épidémiologie , Infections à virus respiratoire syncytial/mortalité , Infections à virus respiratoire syncytial/thérapie , Infections de l'appareil respiratoire/mortalité , Infections de l'appareil respiratoire/thérapie , Facteurs de risque , Résultat thérapeutiqueRÉSUMÉ
A human herpesvirus 7 (HHV-7) indirect immunofluorescence antibody avidity test was developed and used with an existing human herpesvirus 6 (HHV-6) antibody avidity test to detect and distinguish low-avidity antibodies to HHV-6 and HHV-7 and hence the respective primary infections. With sera from 269 British children aged 0 to 179 weeks, the tests showed that most (10 of 98 serum samples [13%]) HHV-6 low-avidity antibody was found in the first year of life, whereas for HHV-7, most (18 of 101 serum samples [20%]) HHV-7 low-avidity antibody was found in the second year of life. Five children had low-avidity antibodies to both viruses. Of nine Japanese children with previously serologically proven primary HHV-6 or HHV-7 infections, eight had low-avidity antibody only to the relevant virus, but one child had low-avidity antibodies to HHV-6 and HHV-7. The avidity tests were applied to five British children and further proof of viral infection was sought by the detection of specific DNA in serum or plasma, and saliva or cerebrospinal fluid. In two children who had low-avidity antibody to HHV-7 but who were seronegative for HHV-6, only HHV-7 was found. Both viruses were detected in one child with low-avidity HHV-7 antibody and high-avidity HHV-6 antibody. In two children with low-avidity antibodies to both viruses, HHV-6 and HHV-7 DNAs were found, confirming dual primary infections and excluding antibody cross-reactivity.
Sujet(s)
Affinité des anticorps , Infections à Herpesviridae/diagnostic , Herpèsvirus humain de type 6/immunologie , Herpèsvirus humain de type 7/immunologie , Immunoglobuline G/immunologie , Adulte , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Enfant d'âge préscolaire , ADN viral/sang , Femelle , Infections à Herpesviridae/virologie , Humains , Immunoglobuline G/sang , Nourrisson , Nouveau-né , Mâle , Réaction de polymérisation en chaîne , Spécificité d'espèceRÉSUMÉ
The prophylactic and pre-emptive use of ganciclovir (GCV) both reduce significantly the incidence of CMV disease after sibling BMT but it is unclear which of these strategies is best for volunteer unrelated donor (VUD) BMT patients. We reviewed 49 consecutive patients, who received a T-depleted VUD BMT (from March 1990 to March 1996) for the treatment of CML in chronic phase, and were CMV seropositive before transplant or had a CMV seropositive donor. Patients were conditioned with cyclophosphamide (120 mg/kg for 2 days) and total body irradiation (13.2-14.4 Gy). Prophylaxis for GVHD was cyclosporin A and methotrexate with ex vivo or in vivo T cell depletion. Twenty-seven patients received pre-emptive GCV if CMV infection was detected by short-term culture before day +120 post BMT. Twenty-two patients received prophylactic GCV from engraftment until day +120 post BMT. The probabilities of CMV infection and disease occurring by 1 year post-BMT were greater in the pre-emptive GCV group than in the prophylactic GCV group (73.8% and 64.0% vs 53.1% and 30.0%, respectively; P=0.04 and 0.07). The incidence of death from CMV disease was similar in both groups (3/12 (25%) vs 3/10 (30%), respectively) and there was no difference in 1 year survival (55.6% vs 54.2%, respectively). New strategies are urgently required for the prevention of CMV disease after T-depleted VUD BMT.
Sujet(s)
Transplantation de moelle osseuse , Infections à cytomégalovirus/prévention et contrôle , Ganciclovir/usage thérapeutique , Adulte , Transplantation de moelle osseuse/immunologie , Transplantation de moelle osseuse/mortalité , Femelle , Humains , Déplétion lymphocytaire , Mâle , Études rétrospectives , Taux de survie , Donneurs de tissus , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND AND OBJECTIVE: Human cytomegalovirus (HCMV) infection and disease remain a major cause of morbidity and mortality after bone marrow transplantation. HCMV disease, especially pneumonitis, may be treated with ganciclovir and immunoglobulin but even so the outcome is poor with mortality rates of 30-70%. It is therefore imperative to treat HCMV infection before it develops into disease. The aim of this article is to describe the main strategies used to prevent HCMV infection and to improve the survival after CMV disease in bone marrow transplant recipients. INFORMATION SOURCES: In the present review, we examined personal papers in this field and articles published in journals covered by the Science Citation Index and Medline. STATE OF THE ART: Major advances have been made in preventing HCMV infection and disease through two different approaches, both of which reduce HCMV induced morbidity and mortality: In pre-emptive therapy, patients are given ganciclovir when HCMV infection is first identified and this is continued 3-4 months after transplantation; in prophylactic therapy ganciclovir is given to all patients at risk of HCMV disease from engraftment up to 3-4 months post transplantation. Each strategy has advantages and disadvantages and there is no evidence for the superiority of one over the other since the overall survival is the same and the incidence of death from HCMV disease is similar. PERSPECTIVES: The use of more sensitive tests such as HCMV PCR or antigenemia may improve the outcome but probably will not eradicate all HCMV disease. Future possible strategies could include adoptive transfer of CD8+ HCMV-specific cytotoxic T lymphocytes clones derived from the donor marrow or boosting donor or patient immunity using subunit anti-HCMV vaccines such as gB or pp65.